The only biomarker clinically used in MI patients is B-type natriuretic peptide (BNP) whose concentration helps to predict the risk of HF [6], but data on its ability to predict LV remodelling are discordant [7–9]. The gene discussed is NPPB; the disease is myocardial infarction.